Nanomedicine strategies to counteract cancer stemness and chemoresistance

Explor Target Antitumor Ther. 2023;4(4):630-656. doi: 10.37349/etat.2023.00157. Epub 2023 Aug 30.

Abstract

Cancer stem-like cells (CSCs) identified by self-renewal ability and tumor-initiating potential are responsible for tumor recurrence and metastasis in many cancers. Conventional chemotherapy fails to eradicate CSCs that hold a state of dormancy and possess multi-drug resistance. Spurred by the progress of nanotechnology for drug delivery and biomedical applications, nanomedicine has been increasingly developed to tackle stemness-associated chemotherapeutic resistance for cancer therapy. This review focuses on advances in nanomedicine-mediated therapeutic strategies to overcome chemoresistance by specifically targeting CSCs, the combination of chemotherapeutics with chemopotentiators, and programmable controlled drug release. Perspectives from materials and formulations at the nano-scales are specifically surveyed. Future opportunities and challenges are also discussed.

Keywords: Drug delivery; cancer stem-like cells; cancer therapy; chemoresistance; nanomedicine.

Publication types

  • Review